ADC Therapeutics
Update in progressADCT (NYSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
ADC Therapeutics SA develops antibody-drug conjugate (ADC) technology in Switzerland and the United States. Its lead product, ZYNLONTA, is a CD19-directed ADC approved in the U.S. (accelerated), with conditional approvals in the EU and China for relapsed/refractory DLBCL after at least two prior therapies. The company is expanding ZYNLONTA into earlier lines and other B-cell lymphomas via LOTIS-5/LOTIS-7 and IITs, while pursuing CD22 and ADCT-602 in IITs. Its preclinical pipeline targets Claudin-6, NaPi2b, PSMA, and ASCT2. Founded 2011, HQ in Epalinges, Switzerland.
Company score
- Sentiment
- -0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.32
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!